Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e81-

  González Barriga, Anchel ^a,b   Mulders, Susan A M ^a,b   Van De Giessen, Jeroen ^b   Hooijer, Jeroen D ^a,c   Bijl, Suzanne ^b   Van Kessel, Ingeborg D G ^a   Van Beers, Josee ^a   Van Deutekom, Judith C T ^b   Fransen, Jack A M ^a   Wieringa, Bé ^a   Wansink, Derick G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa BV   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antisense oligonucleotides; Myotonic dystrophy; RNA processing; RNA silencing; Triplet repeat expansion

Indexed keywords

2' O METHYL PHOSPHOROTHIOATE; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MYOTONIC DYSTROPHY PROTEIN KINASE; NUCLEIC ACID; OLIGONUCLEOTIDE; RIBONUCLEASE; TRIPLET REPEAT ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTISENSE THERAPY; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA MODIFICATION; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC TRANSCRIPTION; MOUSE; MYOBLAST; MYOTONIC DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA CLEAVAGE; RNA INTERFERENCE; RNA SPLICING;

EID: 84878866085     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.9     Document Type: Article

References (50)

1. Groenen, P and Wieringa, B (1998). Expanding complexity in myotonic dystrophy. Bioessays 20: 901-912. (Pubitemid 28554035)
2. Wheeler, TM and Thornton, CA (2007). Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 20: 572-576. (Pubitemid 47462288)
3. Harper, PS (2001). Myotonic Dystrophy. WB Saunders: London, UK.
4. Zerylnick, C, Torroni, A, Sherman, SL and Warren, ST (1995). Normal variation at the myotonic dystrophy locus in global human populations. Am J Hum Genet 56: 123-130.
5. Rau, F, Freyermuth, F, Fugier, C, Villemin, JP, Fischer, MC, Jost, B et al. (2011). Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 18: 840-845.
6. Mahadevan, MS, Yadava, RS, Yu, Q, Balijepalli, S, Frenzel-McCardell, CD, Bourne, TD et al. (2006). Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 38: 1066-1070. (Pubitemid 44325934)
7. Mulders, SA, van Engelen, BG, Wieringa, B and Wansink, DG (2010). Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. Hum Mol Genet 19(R1): R90-R97.
8. Mulders, SA, van den Broek, WJ, Wheeler, TM, Croes, HJ, van Kuik-Romeijn, P, de Kimpe, SJ et al. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 106: 13915-13920.
9. Wheeler, TM, Sobczak, K, Lueck, JD, Osborne, RJ, Lin, X, Dirksen, RT et al. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325: 336-339.
10. Lee, JE, Bennett, CF and Cooper, TA (2012). RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci USA 109: 4221-4226.
11. François, V, Klein, AF, Beley, C, Jollet, A, Lemercier, C, Garcia, L et al. (2011). Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol 18: 85-87.
12. Tashiro, F and Ueno, Y (1978). Ribonuclease H from rat liver. I. Partial purification and characterization of nuclear ribonuclease H1. J Biochem 84: 385-393. (Pubitemid 9017131)
13. Kurreck, J (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644. (Pubitemid 36532522)
14. Eisen, JS and Smith, JC (2008). Controlling morpholino experiments: don't stop making antisense. Development 135: 1735-1743.
15. Morita, K, Hasegawa, C, Kaneko, M, Tsutsumi, S, Sone, J, Ishikawa, T et al. (2002). 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett 12: 73-76. (Pubitemid 34008572)
16. Krol, J, Fiszer, A, Mykowska, A, Sobczak, K, de Mezer, M and Krzyzosiak, WJ (2007). Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 25: 575-586. (Pubitemid 46274449)
17. Schroder, W, Cloonan, N, Bushell, G and Sculley, T (2004). Alternative polyadenylation and splicing of mRNAs transcribed from the human Sin1 gene. Gene 339: 17-23. (Pubitemid 39201124)
18. Furling, D, Lemieux, D, Taneja, K and Puymirat, J (2001). Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblasts. Neuromuscul Disord 11: 728-735. (Pubitemid 32930021)
19. Kozlowski, P, de Mezer, M and Krzyzosiak, WJ (2010). Trinucleotide repeats in human genome and exome. Nucleic Acids Res 38: 4027-4039.
20. Gerwins, P, Blank, JL and Johnson, GL (1997). Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J Biol Chem 272: 8288-8295. (Pubitemid 27147785)
21. Groenen, PJ, Wansink, DG, Coerwinkel, M, van den Broek, W, Jansen, G and Wieringa, B (2000). Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties. Hum Mol Genet 9: 605-616. (Pubitemid 30154019)
22. Tiscornia, G and Mahadevan, MS (2000). Myotonic dystrophy: the role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios. Mol Cell 5: 959-967.
23. Bhindi, R, Fahmy, RG, Lowe, HC, Chesterman, CN, Dass, CR, Cairns, MJ et al. (2007). Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of smallmoleculenucleic acid-based gene-silencing strategies. Am J Pathol 171: 1079-1088. (Pubitemid 47582883)
24. Henry, SP, Giclas, PC, Leeds, J, Pangburn, M, Auletta, C, Levin, AA et al. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281: 810-816. (Pubitemid 27203815)
25. Rudin, CM, Holmlund, J, Fleming, GF, Mani, S, Stadler, WM, Schumm, P et al. (2001). Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7: 1214-1220. (Pubitemid 32708672)
26. Mooers, BH, Logue, JS and Berglund, JA (2005). The structural basis of myotonic dystrophy from the crystal structure of CUG repeats. Proc Natl Acad Sci USA 102: 16626-16631. (Pubitemid 41688827)
27. Koizumi, M (2006). ENA oligonucleotides as therapeutics. Curr Opin Mol Ther 8: 144-149.
28. Robb, GB, Brown, KM, Khurana, J and Rana, TM (2005). Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol 12: 133-137.
29. Sobczak, K, Wheeler, TM, Wang, W and Thornton, CA (2013). RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther 21: 380-387.
30. Wansink, DG and Wieringa, B (2003). Transgenic mouse models for myotonic dystrophy type 1 (DM1). Cytogenet Genome Res 100: 230-242. (Pubitemid 37467811)
31. Smith, PJ, Zhang, C, Wang, J, Chew, SL, Zhang, MQ and Krainer, AR (2006). An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15: 2490-2508. (Pubitemid 44288702)
32. Fiszer, A, Olejniczak, M, Switonski, PM, Wroblewska, JP, Wisniewska-Kruk, J, Mykowska, A et al. (2012). An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. BMC Mol Biol 13: 6.
33. Doma, MK and Parker, R (2007). RNA quality control in eukaryotes. Cell 131: 660-668. (Pubitemid 350087205)
34. Nakamori, M, Gourdon, G and Thornton, CA (2011). Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther 19: 2222-2227.
35. Chiu, YL and Rana, TM (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048. (Pubitemid 37093614)
36. Amarzguioui, M, Holen, T, Babaie, E and Prydz, H (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31: 589-595. (Pubitemid 36175948)
37. Braasch, DA, Jensen, S, Liu, Y, Kaur, K, Arar, K, White, MA et al. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975. (Pubitemid 36807714)
38. Sun, X, Rogoff, HA and Li, CJ (2008). Asymmetric RNA duplexes mediate RNAinterference in mammalian cells. Nat Biotechnol 26: 1379-1382.
39. Chu, CY and Rana, TM (2008). Potent RNAi by short RNA triggers. RNA 14: 1714-1719.
40. Summerton, JE (2007). Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 7: 651-660. (Pubitemid 46681848)
41. Wansink, DG, van Herpen, RE, Coerwinkel-Driessen, MM, Groenen, PJ, Hemmings, BA and Wieringa, B (2003). Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. Mol Cell Biol 23: 5489-5501. (Pubitemid 36951318)
42. Hu, J, Matsui, M, Gagnon, KT, Schwartz, JC, Gabillet, S, Arar, K et al. (2009). Allelespecific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27: 478-484.
43. Seznec, H, Lia-Baldini, AS, Duros, C, Fouquet, C, Lacroix, C, Hofmann-Radvanyi, H et al. (2000). Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet 9: 1185-1194. (Pubitemid 30248604)
44. Ye, J, Coulouris, G, Zaretskaya, I, Cutcutache, I, Rozen, S and Madden, TL (2012). Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13: 134.
45. Owczarzy, R, Tataurov, AV, Wu, Y, Manthey, JA, McQuisten, KA, Almabrazi, HG et al. (2008). IDT SciTools: a suite for analysis and design of nucleic acid oligomers. Nucleic Acids Res 36(Web Server issue): W163-W169.
46. Bustin, SA, Benes, V, Garson, JA, Hellemans, J, Huggett, J, Kubista, M et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
47. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
48. Vandesompele, J, De Preter, K, Pattyn, F, Poppe, B, Van Roy, N, De Paepe, A et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
49. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Developmentof an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbentassay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25. (Pubitemid 34492838)
50. van den Broek, WJ, Nelen, MR, Wansink, DG, Coerwinkel, MM, te Riele, H, Groenen, PJ et al. (2002). Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins. Hum Mol Genet 11: 191-198. (Pubitemid 34157011)